29271 results about "Amide" patented technology

The present invention relates to the atomic layer deposition (“ALD”) of high k dielectric layers of metal silicates, including hafnium silicate. More particularly, the present invention relates to the ALD formation of metal silicates using metal organic precursors, silicon organic precursors and ozone. Preferably, the metal organic precursor is a metal alkyl amide and the silicon organic precursor is a silicon alkyl amide.

The present invention relates to the atomic layer deposition (“ALD”) of high k dielectric layers of metal oxides containing Group 4 metals, including hafnium oxide, zirconium oxide, and titanium oxide. More particularly, the present invention relates to the ALD formation of Group 4 metal oxide films using an metal alkyl amide as a metal organic precursor and ozone as a co-reactant.

Methods for forming metal silicate films are provided. The methods comprise contacting a substrate with alternating and sequential vapor phase pulses of a metal source chemical, a silicon source chemical and an oxidizing agent. In preferred embodiments, an alkyl amide metal compound and a silicon halide compound are used. Methods according to preferred embodiments can be used to form hafnium silicate and zirconium silicate films with substantially uniform film coverages on substrate surfaces comprising high aspect ratio features (e.g., vias and/or trenches).

A precursor for the deposition of a thin film by atomic layer deposition is provided. The compound has the formula MxLy where M is a metal and L is an amidrazone-derived ligand or an amidate-derived ligand. A process of forming a thin film using the precursors is also provided.

The present invention relates to the discovery that certain non-naturally occurring, non-peptide amide compounds and amide derivatives, such as oxalamides, ureas, and acrylamides, are useful flavor or taste modifiers, such as a flavoring or flavoring agents and flavor or taste enhancer, more particularly, savory (the “umami” taste of monosodium glutamate) or sweet taste modifiers,—savory or sweet flavoring agents and savory or sweet flavor enhancers, for food, beverages, and other comestible or orally administered medicinal products or compositions.

A breathable composite sheet material, a method for making such a sheet material, and an absorbent article utilizing the sheet material are provided. The composite sheet material is comprised of a thermoplastic film adhered directly to a fibrous substrate. The thermoplastic film comprises at least 50% by weight of a polymer material from the group of block copolyether esters, block copolyether amides and polyurethanes. The substrate comprises a fibrous web of at least 50% by weight of polyolefin polymer synthetic fibers. The composite sheet exhibits a peel strength of at least 0.1 N/cm, a dynamic fluid transmission of less than about 0.75 g/m² when subjected to an impact energy of about 2400 joules/m², and a moisture vapor transmission rate, according to the desiccant method, of at least 1500 g/m²/24 hr. The absorbent article comprises (a) a topsheet; (b) a backsheet; and (c) an absorbent core located between the topsheet and the backsheet; wherein the backsheet comprises the non-porous, substantially fluid impermeable, moisture vapor permeable composite sheet material described above. The composite sheet material is oriented such that the film layer of the composite sheet material faces toward the absorbent core. The absorbent article may comprise a disposable diaper.

Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming lactam bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, substitution of carboxy terminal amino acids, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (K-RNRNNIA) and SEQ ID NO: 28 (KRNR).

The present invention is directed to certain diaryl amide compounds as NS3-Serine protease inhibitors of hepatitis C virus. A particularly preferred compound is of the formula:

The present invention provides bioactive polymer compositions that can be formulated to release a wound healing agent at a controlled rate by adjusting the various components of the composition. The composition can be used in an external wound dressing, as a polymer implant for delivery of the wound healing agent to an internal body site, or as a coating on the surface of an implantable surgical device to deliver wound healing agents that are covalently attached to a biocompatible, biodegradable polymer and/or embedded within a hydrogel. Methods of using the invention bioactive polymer compositions to promote natural healing of wounds, especially chronic wounds, are also provided. Examples of biodegradable copolymer polyesters useful in forming the blood-compatible, hydrophilic layer or coating include copolyester amides, copolyester urethanes, glycolide-lactide copolymers, glycolide-caprolactone copolymers, poly-3-hydroxy butyrate-valerate copolymers, and copolymers of the cyclic diester monomer, 3-(S)[(alkyloxycarbonyl)methyl]-1,4-dioxane-2,5-dione, with L-lactide. The glycolide-lactide copolymers include poly(glycolide-L-lactide) copolymers formed utilizing a monomer mole ratio of glycolic acid to L-lactic acid ranging from 5:95 to 95:5 and preferably a monomer mole ratio of glycolic acid to L-lactic acid ranging from 45:65 to 95:5. The glycolide-caprolactone copolymers include glycolide and ε-caprolactone block copolymer, e.g., Monocryl or Poliglecaprone.

The present invention generally encompasses a medical article, such as a medical device or coating comprising an agent or combination of agents, wherein the agent is distributed throughout a polymeric matrix. The polymeric matrix comprises an agent and a poly(ester amide) having a design that was preselected to provide a predetermined release rate of the combination of agents from the medical article.

The invention is an epoxy resin based adhesive composition comprising an epoxy resin and a compound comprising an elastomeric prepolymer residue selected from the group of a polyurethane, a polyurea and a polyurea polyurethane having isocyanate end groups, the isocyanate end groups of said prepolymer residue being capped by a capping compound selected from the group consisting of a primary aliphatic, cycloaliphatic, heteroaromatic and araliphatic amine, a secondary aliphatic, cycloaliphatic, aromatic, heteroaromatic and araliphatic amine, a thiol and an alkyl amide, said capping compound being bound to the end of the polymer chain of the elastomeric prepolymer in a manner such that the end to which it is bonded no longer has a reactive group. In addition to the capping compound defined above above, a capping compound selected from the group consisting of a phenol and a polyphenol can be used for capping the isocyanate end groups of the prepolymer residue

The present invention relates to a compound represented by Formula (I):

(wherein Ar₁ represents an imidazolyl group which may be substituted with 1 to 3 substituents; Ar₂ represents a pyridinyl group, a pyrimidinyl group, or a phenyl group which may be substituted with 1 to 3 substituents; X₁ represents (1) —C≡C— or (2) a double bond etc. which may be substituted; R¹ and R² represent, for example, a C1-6 alkyl group or C3-8 cycloalkyl group which may be substituted)

or a pharmacologically acceptable salt thereof and to the use thereof as pharmaceutical agents. The object of the present invention is to find a therapeutic or preventive agent for diseases caused by Aβ. According to the present invention, a therapeutic or preventive agents for diseases caused by Aβ can be provided.

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, hyperglycemia, impaired glucose tolerance, metabolic syndrome (Syndrome X or insulin resistance syndrome), glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.

The present invention provides biodegradable polymer particle delivery compositions for delivery of macromolecular biologics, for example in crystal form, based on polymers, such as polyester amide (PEA), polyester urethane (PEUR), and polyester urea (PEU) polymers, which contain amino acids in the polymer. The polymer particle delivery compositions can be formulated either as a liquid dispersion or a lyophilized powder of polymer particles containing bound water molecules with the macromolecular biologics, for example insulin, dispersed in the particles. Bioactive agents, such as drugs, polypeptides, and polynucleotides can also be delivered by using particles sized for local, oral, mucosal or circulatory delivery. Methods of delivering a macromolecular biologic with substantial native activity to a subject, for example orally, are also included.

The invention belongs to the field of surface treatment, and relates to a stainless steel cleaner. The cleaner comprises a nonionic surfactant, an anionic surfactant, a complexing agent, a degreasing agent and deionized water, wherein the degreasing agent is one of amide, and a mixture of amide and hydramine. An environmentally-friendly cleaner comprising the amide or the hydramine, a composite surfactant and the like removes grease under the alkalescent condition, and has good cleaning effect due to the permeation effect of the composite surfactant on the grease and an oxide layer. The invention also relates to a stainless steel cleaning method. The stainless steel cleaner and the stainless steel cleaning method are widely applied to the treatment of various stainless steel surfaces.